Back to Newsroom

Alder BioPharmaceuticals Appoints Paul B. Cleveland to Board of Directors

BOTHELL, Wash., Aug. 20, 2015 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced the appointment of Paul B. Cleveland to its Board of Directors. “We are delighted to welcome Paul to our Board of Directors and as Chairman of our Audit Committee,” said Randall C. Schatzman, Ph.D., President and Chief Executive Officer of Alder. “Paul’s extensive experience in finance and corporate strategy in our industry will be extremely valuable as we continue to advance our lead clinical candidate, ALD403, for the prevention of migraine toward the market.”

Click here to read more